Hotline: 86-023-62505954
About Us / about us
News / news
Video VIDEO
About us / 公司简介
Chongqing Pharmaceutical Research Institute was founded in 1950 andused to be a leading public institution fully dedicated to pharmaceutical research and development in Southwest China. In 2001, it underwent a historical event that the ownership of CPRI was converted to jointly owned by Shanghai Fosun Pharmaceutical (Group) Co., Ltd and Chongqing Pharmaceutical (Group) Co., Ltd, whereby Chongqing Pharmaceutical Research Institute Co., Ltd was founded (hereinafter referred to as the CPRI).After decades of development, CPRI had built an integrated new drug development system with full and multi cross-disciplinary supports, including innovative drug (API and Formulation) development, pharmacological and toxicological evaluation, CRO services and pilot level scale-up manufacturing sites complying with the cGMP requirements;also, a Chiral Drug R&D platform; a Drug Delivery System (DDS)platform featured in taste-masked drug delivery technology, targeted and controlled release technology ...
News / 新闻动态
Press Release_CPRI_BMGF
Chongqing Pharmaceutical Research Institute Co., Ltd. has received funding from the Bill & Melinda Gates Foundation for the development of a large-scale semi-synthetic Artemisinin processIn July 2018, Chongqing Pharmaceutical Research Institute Co., Ltd (“CPRI”), the Research and Development platform of Fosun Pharma, was awarded with 450,000 USD from the Bill & Melinda Gates Foundation (“Gates Foundation”), a non-profit organization, for the development of a semi-synthetic Artemisinin manufacturing process.Malaria is one of the leading fatal infectious diseases in the world. According to the 2017 World Malaria Report from WHO (World Health Organization), about half of the population in 91 countries around the world are still threatened by malaria, with 216 million malaria cases and 445 thousand malaria deaths reported at the end of 2016. New artemisinin-based combination therapy is used as the first-line treatment for malaria in over 80 countries. Synbiowatch has reported ...
2018 - 08 - 23
Press Release_CPRI_BMGF
Chongqing Pharmaceutical Research Institute Co., Ltd. has received funding from the Bill & Melinda Gates Foundation for the development of a large-scale semi-synthetic Artemisinin processIn July 2018, Chongqing Pharmaceutical Research Institute Co., Ltd (“CPRI”), the Research and Development platform of Fosun Pharma, was awarded with 450,000 USD from the Bill & Melinda Gates Foundation (“Gates Foundation”), a non-profit organization, for the development of a semi-synthetic Artemisinin manufacturing process.Malaria is one of the leading fatal infectious diseases in the world. According to the 2017 World Malaria Report from WHO (World Health Organization), about half of the population in 91 countries around the world are still threatened by malaria, with 216 million malaria cases and 445 thousand malaria deaths reported at the end of 2016. New artemisinin-based combination therapy is used as the first-line treatment for malaria in over 80 countries. Synbiowatch has reported ...
2018 - 08 - 23
To be added...
To be added...
2013 - 12 - 11
To be added...
To be added...
2017 - 03 - 09
Video / 公司视频

 
Products
/ products
 Contact Us
No.565 · NanAnDistrict · ChongQing
Tel: 86-023-62505954
86-023062505956
E-mail:cpri@cpri.com.cn
Copyright ©2005 - 2013 Chongqing Pharmaceutical Research Institute
犀牛云提供企业云服务
进入手机网站